This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Marilyn Pearl, MD

Am J Dis Child. 1977;131(6):650-652.

Abstract
• An uncommon, but lethal, toxic side effect of busulfan (Myleran) therapy for chronic myelogenous leukemia is pulmonary fibrosis. A 16-month-old male infant treated for 11 months with busulfan for chronic myelogenous leukemia is, we believe, the first case of "busulfan lung" in the pediatric age group to be reported. Progressive roentgenographic changes in the lung of a diffuse intra-alveolar and interstitial pattern were noted. The patient died after a four-day episode of cough, fever, and progressive dyspnea. At autopsy, no evidence of infection or leukemic infiltrates were seen in the lungs. Characteristic histologic findings as a result of busulfan therapy were observed in the lung and pancreas.

(Am J Dis Child 131:650-652, 1977)

Author Affiliations
From the Department of Radiology, New York Medical College and Metropolitan Hospital Center, New York.

Footnotes
Reprint requests to Department of Radiology, Pediatric Radiology Division, Metropolitan Hospital Center, 1901 First Ave, New York, NY 10029 (Dr Pearl).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of High-Dose Busulfan Plus Melphalan As Consolidation in Metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l'Enfant
Oberlin et al.
JCO 2006;24:3997-4002.
ABSTRACT | FULL TEXT  

Pulmonary Toxicity of Antineoplastic Drugs
Batist and Andrews
JAMA 1981;246:1449-1453.
ABSTRACT